Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 18200040

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Leukemia
Publication date
2008 Apr
First author
San-Miguel JF

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      San-Miguel JF
      type
      Author
    2. name
      Richardson PG
      type
      Author
    3. name
      Sonneveld P
      type
      Author
    4. name
      Schuster MW
      type
      Author
    5. name
      Irwin D
      type
      Author
    6. name
      Stadtmauer EA
      type
      Author
    7. name
      Facon T
      type
      Author
    8. name
      Harousseau JL
      type
      Author
    9. name
      Ben-Yehuda D
      type
      Author
    10. name
      Lonial S
      type
      Author
    11. name
      Goldschmidt H
      type
      Author
    12. name
      Reece D
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      San-Miguel JF
      type
      Author
    2. name
      Richardson PG
      type
      Author
    3. name
      Sonneveld P
      type
      Author
    4. name
      Schuster MW
      type
      Author
    5. name
      Irwin D
      type
      Author
    6. name
      Stadtmauer EA
      type
      Author
    7. name
      Facon T
      type
      Author
    8. name
      Harousseau JL
      type
      Author
    9. name
      Ben-Yehuda D
      type
      Author
    10. name
      Lonial S
      type
      Author
    11. name
      Goldschmidt H
      type
      Author
    12. name
      Reece D
      type
      Author
    bibliography ids
    1. nci-bib-90406cd9474f0d2bc7dd1227
    book metadata
    content sha256
    0aa626ecd3971eda0cc953fc86ba40bc75ea0dc7f230488ed5807fb38fc3c5e4
    document type
    citation
    dois
    1. 10.1038/sj.leu.2405087
    electronic publication date
    display
    2008 Jan 17
    precision
    day
    year
    2008
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:18200040
    immutable id
    pubmed:18200040@0aa626ecd3971eda0cc953fc86ba40bc75ea0dc7f230488ed5807fb38fc3c5e4
    journal
    abbreviation
    Leukemia
    issn electronic
    1476-5551
    issn print
    0887-6924
    issue
    4
    name
    Leukemia
    nlm unique id
    8704895
    pages
    842-9
    volume
    22
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      18200040
      provenance
      batch id
      89a0f2206e11ca092d02
      provider
      NCBI PubMed ESummary
      record sha256
      1f03e4b003e745c7f644b274922f6d62c734bc8874da07b0b4815cc7a403c493
      response sha256
      7b1c355120884a7a596bcf7b4a243dc12308b7f7f0914c3fc71b0c8e8d79c708
      retrieved at
      2026-09-09T23:46:16.784581+00:00
      publication date
      display
      2008 Apr
      precision
      month
      year
      2008
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Randomized Controlled Trial
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/18200040/
      title
      Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

      Preserved source evidence · Not medical advice